UPDATE 01. September 2021: Dr. David Martin - Covid vaccine mRNA code is a BIOWEAPON developed via a digital SIMULATION

UPDATE 01. August 2021: SARS-CoV-2 - InflammoThrombotic Response (ITR)

UPDATE 21. March 2021: Masterclass on SARS-CoV-2 + Gain of Function Research

UPDATE 17. January 2021: Almost a third of recovered Covid patients return to hospital in five months and one in eight die

Almost 90% of recovered COVID-19 patients report persistent symptoms

COVID-19 patients with persistent symptoms
Source: Carfi A, et al. JAMA. 2020;doi:10.1001/jama.2020.12603 Source/Disclosures

By Eamon N. Dreisbach - 13. August 2020

Almost 90% of patients who recovered from COVID-19 reported at least one persistent symptom, according to a study of 143 patients published in JAMA.

“For the clinicians, the game is not over when you discharge the subjects from the acute ward,” Angelo Carfi, MD, of the geriatrics department at Agostino Gemelli University Hospital in Rome, told Healio. “We should try to figure out a way to help them to recover as quickly as they can.”

Carfi and colleagues followed up with COVID-19 patients from Agostino Gemelli University Hospital who met WHO criteria for quarantine discontinuation — two negative tests for SARS-CoV-2 within 24 hours, absence of fever for 3 consecutive days and improvements in other symptoms.

The researchers collected information on specific symptoms related to COVID-19 via a standardized questionnaire.

On the questionnaire, patients were asked to recall the presence of COVID-19 symptoms and if the symptom continued at the time of the visit. The researchers used the EuroQol scale from 0 to 100 to evaluate patients’ quality of life before and after COVID-19, with a difference of 10 points indicating a worsened quality of life.

During their hospitalization, 72.7% of patients showed symptoms of pneumonia. The average patient age was 56, and average length of stay was 13.5 days. A total of 15% of patients underwent noninvasive ventilation, and 5% had invasive ventilation.

The researchers analyzed patients an average of 60 days after the onset of COVID-19 symptoms. Only 12.6% of patients had no COVID-19 symptoms at the time of evaluation. The remaining 87.4% reported symptoms: 32% showed one or two symptoms and 55% showed three or more symptoms. No participants showed fever or signs of acute COVID-19, the researchers reported. Almost half — 44% — of patients reported a lower quality of life following COVID-19.

Carfi said comradery across medical specialties was useful during the course of the study.

“Usually in a hospital it is very difficult to collaborate across different specialties because everyone is focusing on their own work,” Carfi said. “In this case, everything was very easy and smooth — everyone wanted to join the team and to do their part for COVID-19.”



Dr. David Martin - Covid vaccine mRNA code is a BIOWEAPON developed via a digital SIMULATION

01. SEPTEMBER 2021

channel image

Health Ranger Report

Dr. David Martin interviewed by Mike Adams.


SARS-CoV-2 - InflammoThrombotic Response (ITR)

By Dr. Richard Fleming  - 01. July 2021

The following diagram shows how SARS-CoV-2 is passed from person to person through respiratory droplets. Once inside the body the virus will invade our cells and reproduce itself. In response to the virus our immune system will attack the invader launching first a response from T-cells designed to kill the cells infected with the virus and later an antibody response designed to kill the virus before it gets into another cell.

This diagram also shows how too much of a good thing can cause harm to the body. When our VIRAL immune response, either because of other health problems we have (comorbidities) produce too much response OR because there is too much of the virus (e.g. vaccines) in our body; the outcome is INFLAMMATION and BLOOD CLOTTING [InflammoThrombotic Response – ITR] that can kill us (COVID-19).

The document numbers listed on the diagram below match the numbered documents providing links to the research as well as other materials not only explaining these issues but also the Gain-of-Function (GoF) research responsible for the development of this man-made virus.

Richard M Fleming, PhD, MD, JD can be contacted via email: 

SARS-CoV-2: Documents 1720144145146147148153, 156, 163, 164, 165, 169170.

InflammoThrombotic Response (ITR): Documents 181921333749.
Treatment Information & Immunity: Document 406768,
Gain-of-Function (With HIV-gp120; PRRA & Prion-like Domain): Documents 7914151621222635363839414243444546474850545657160166.

BIOWEAPON: 5859606162.
Vaccines: Documents 12313243132515253555665.
143, 149150154155158159167.

Enters Nucleus with DNA: Documents 101112636466157.
Antibody Dependent Enhancement of Virus: Documents 456167.

Neurologic - Central Nervous System - Brain: 823252728293034.
1. EUA Requirements by FDA

October 2020

2. Pfizer EUA document

December 10, 2020

3. Moderna EUA Document

December 17, 2020

4. SARS-CoV-1 Antibody Dependent Enchancement (ADE)

July 5, 2011

5. ADE shown in animals including primates

January 2, 2021

6. ADE (Osaka Paper) showing antibodies to NTD increase infectivity of SARS-CoV-2

December 18, 2020

7. Prion-like Domains

March 29,, 2020

8. Amyloid Precursor Proteins and Neurologic Disease

May 21, 2019

9. Amyloidosis and Prion Diseases

October 26, 2010

10. SARS-CoV-2 RT back into human DNA

December 13, 2020

11. Platlets and LINE-1 to Generate RNA-DNA Hybrids with Reverse Transcriptase

April 2018

12. Reverse Transcription Produces Mechanism for Long Term Survival and Recurrent Infections

January 9, 2019

13. Pfizer vaccines contains 13 billion mRNA repetitions in the low dose of 30-micrograms.

December 25, 2020

14. Baric & Zhengli Shi re-engineer the HKU4 spike to increase Corona Virus Infectivity. Gain-of-Function (GoF)

September 2015

15. SARS-CoV-2 Gain-of-Function Hall of Shame

October 1, 2020

16. Evidence that SARS-CoV-2 is not naturally evolved

July 1, 2020

17. South African Mutation of SARS-CoV-2

December 22, 2020

18. InflammoThrombotic Response (ITR)

August 18,2020

19. Massive Blood Clots Kill COVID Patients

August 18, 2020

20. Cryo-Electron Tomography of SARS-CoV-2 showing spike proteins

October 9, 2020

21. PRRA Superantigen increases inflammation

October 13, 2020

22. PRRA Insert essential for infection of human lung cells and brain

May 1, 2020

23. SARS-CoV-2 Spike protein crosses the blood brain barrier in mice study

December 16, 2020

24. Neurological adverse events associated with vaccines

June 2002

25. SARS-CoV-2 Invades Brain

November 30, 2020

26. Neuropilin-1binds to Furin (PRRA) Cleavage site to increase Infectivity.

November 13, 2020

27. Spike Protein Crosses BBB to Infect Brain

November 30, 2020

28. Fatal Invasion of Brain by SARS-CoV-2 Depends upon ACE2.

January 15, 2021

29. SARS-CoV-2 Interferes With Recognition of the Severity of Hypoxemia.

July 28, 2020

30. RNA can Behave like Prions.

July 1, 2020

31. Influenza mRNA Spreads Throughout Body and Found in Lungs, Brain, Heart for 14-days.

October 1995

32. Moderna mRNA Vaccine for Influenza Spreads Throughout Body.

March 24, 2017

33. How Immune Cells Cross the Blood-Brain Barrier.

February 4, 2019

34. Neuroinvasion, Encephalitis and Neuron Death with SARS-CoV-2.

January 19, 2021

35. Jean claude Perez § Luc Montagnier - COVID-19, SARS and Bats Coronaviruses Genomes Unexpected Exogenous RNA Sequences

May 29, 2020

36. Jean claude Perez § Luc Montagnier - COVID-19, COVID-19, SARS and Bats Coronaviruses Genomes Peculiar Homologous RNA Sequences 

July 7, 2020

37. Autopsy Findings of InflammoThrombotic Response (ITR) in Patients with COVID-19

JAugust 18, 2020

38. TMPRSS2 and Furin Both Essential for SARS-CoV-2 Infection of Cells.

July 23, 2020

39. Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1

March 22, 2020

40. Treatment of SARS-CoV-2 & COVID-19.
February 8, 2021
41. Evidence of Gain-of-Function.

September 14, 2020

42. Gain-of-Function Hall of Shame.

October 1, 2020

43. Origins of SARS-CoV-2.

February 7, 2021

44. Genetic Structure of SARS-CoV-2.
October 16, 2020
45. Origins of SARS and PRRA.

August 12, 2020

46. The Corona Conspiracy.

October 2020

47. Probabilities of SARS-CoV-2 Origin.

November 12, 2020

48. The Fauci COVID-19 Dossier.

February 18, 2021

49. Primate studies show Inflammation in Brain & Lewy Bodies.

February 23, 2021

50. Patent for PRRA Furin Cleavage Site with Certain Patent Rights Owned by U.S. Governmnent (NIH).

May 29, 2007

51. Janssen (Johnson & Johnson) EUA Document.

February 26, 2021

52. Ad26 [J & J]Prior Studies Reveal Only Temporary Immunity.

July 18, 2012

53. The Coxsackie & Adenovirus Receptor (CAR).

June 8, 1999

54. Deleted Wuhan Databases.

February 23, 2021

55. CDC Document on Adenovirus Vaccines.

January 8, 2020

56. COVID-19 Vaccines and Brain Injury.

April 10, 2021

57. SARS-CoV-2 Accelerates Amyloid Formation.

April 12, 2021

58. SARS-CoV-2 Is an Unrestricted Bioweapon.

Released April 24, 2021

59. SARS-CoV-2 is a Sophisticated Lab Modification.

Released April 24, 2021

60. CNN Lies and Misinformation.

September 14, 2020

61. SARS-CoV-2 - A Scientific Discussion of Lab Origin.

March 25, 2021

62. Lethal Deception.

April 22, 2021

63. Reverse Transcription of SARS-CoV-2 in Human Cells.

March 29, 2021

64. Evidence in Support of SARS-CoV-2 (Viral)-Human Cell Chimers.

March 29, 2021

65. Rethinking Vaccine Safety.

June 24, 2021

66. SARS-CoV-2 Reverse Transcription (RT) Integration into Human DNA.

May 6 , 2021

67. Immunity to SARS-CoV-2 Independent of Severity of SARS-CoV-2/COVID-19 Infection.

June 4, 2021

68. Italian Treatment Recommendations.

March 20, 2021

69. Commenting on Chloroquine.

March 2, 2020

70. Interleukin-6 (IL-6) levels.

April 11, 2020

71. Hydroxychloroquine (HCQ).

April 14, 2020

72. ACEI & ARBs.

May 8, 2020

73. Anti-virals.

January 27, 2020

74. Masks.

April 6, 2020

75. IL-6 Inhibitors.

May 29, 2020

76. Quantitative Nuclear Imaging of Disease.

July 24, 2019

77. Treating QTc Prolongation.

June 25, 2009

78. Hydroxychloroquine better than Chloroquine.

March 14, 2020

79. Nuclear Imaging of Infections.

January 1, 2008

80. Toll-like Receptors.

January 1, 2008

81. Nebulized Azithromycin.


82. Mesenchymal Stem Cells.

February 18, 2020

83. TMPRSS2 and Furin Cleavage Receptors.

May 20, 2020

84. Hydroxychloroquine and Azithromycin.

April 1, 2020

85. Cuban Interferon.

March 13, 2020

86. IL-6 levels Predict Respiratory Failure.

April 1, 2020

87. Vitamin D and Steroids.

April 2020

88. Quantifying Changes in Disease & Treatment Outcomes.

January 17, 2020

89. Ivermectin Protects Nuclear Pore Complex (NPC).

March 29, 2020

90. Convalescent Plasma.

April 3, 2020

91. Multiple Drug Considerations.

May 12, 2020

92. Early Results of Convalescent Plasma.

April 13, 2020

93. N-95 Masks.

February 12, 2020

94. Face Masks in Symptomatic Individuals.

April 10, 2020

95. Decreasing Ventilator Tidal Volume (TV) to Reduce Deaths.

May 4, 2000

96. Lopinavir-Ritonavir Not Successful.

May 7, 2020

97. Reduce TV on Ventilators for Patients with ARDS to Reduce Deaths.

July 22, 2004

98. Remdesivir.

April 10, 2020

99. ACEI and ARBs in the Patients with Heart Disease.

May 1, 2020

100. Multiple Treatment Considerations.

April 28, 2020

101. Rethinking ACEI and ARBS.

April 23, 2020

102. Simple Ventilator & Breathing Terms for Students Using Ventilators.


103. Prone Positioning of Patients Saves Lives.

June 6, 2013

104. Prone Positioning of Patients.

April 8, 2020

105. Remdesivir.

June 2020

106. Treating the InflammoThrombotic Response (ITR).

May 6, 2020

107. SARS-CoV-2 Genome.

May 4, 2020

108. Neutralizing Antibodies.

May 18, 2020

109. Transmission of SARS-CoV-2.

April 15, 2020

110. Centers for Disease Control (CDC) & Emergency Use Authorization (EUA).

April 13, 2020

111. ACEI and ARBs in the Patients with Hypertension (High Blood Pressure).

April 22, 2020

112. Nebulized Antibiotics.

June 2015

113. Nebulized Antibiotics with Lung Disease.

April 1, 2016

114. Thinking About the Pharmacodynamics of Antibiotics.

Deember 12, 2011

115. Immune Response and Various Antibiotics.

December 2015

116. Azithromycin and Zika Virus.

December 13, 2016

117. Doxycycline.

May 9, 2020

118. Aminoquinolines.

April 7, 2020

119. Chloroquine Zinc Ionophore.

October 1, 2014

120. Transmembrane protease serine 2 (TMPRSS2).

April 16, 2020

121. Hydroxychloroquine - NOT alone.

April 16, 2020

122. Primaquine and Newcastle Virus.

October 1974

123. Convalescent Plasma and Viral Infections.

January 1, 2015

124. Neutralizing Antibodies.

March 15, 2020

125. Esmolol for QTc Prolongation.

March 13, 2020

126. Drugs to Avoid with Long QT Syndrome.

April 26, 2013

127. Tocilizumab.


128. Tocilizumab is Effective for ITR.

April 14, 2020

129. Tocilizumab Treatment of COVID-19 Respiratory Failure.

March 27, 2020

130. Tocilizumab and Castleman Disease.

November 2008

131. Janus Kinases.

November 30, 2004

132. Interferon Combination Therapies.

May 8, 2020

133. QTc Prolongation and Tachycardia with Ventolin (Albuterol).

June 28, 2016

134. Chloroquine Reduces Interleukins.

November 29, 2005

135. Zinc (Zn++) Ionophore.

April 9, 2020

136. Interleukin-6 (IL-6) and Steroid Resistance.

December 26, 2012

137. Inhaled Corticosteroids.

March 8, 2010

138. Inhaled Methylprednisolone.

March 30, 2020

139. Innate Immunity.

June 17, 2014

140. Clindamycin and TMPRSS2.

February 18, 2020

141. Heparin Inhibits S1 Spike Protein Attachment to Heparin Binding Protein Site of Regional Binding Domain (RBD).

June 6, 2020

142. Measuring PCR & The Importance of Providing Successful Treatments - Fleming Treatments Recognized Internationally.

July 1, 2021

143. Graphene Oxide Disrupt SARS-CoV-2 Ability to Infect.

May 14, 2021

144. 30,091SARS-CoV-2 Nucleotide Bases.

July 14, 2021

145. The SARS-CoV-2 Virus.

June 2020

146. Recovery of Wuhan Lab Data.

June 22, 2021

147. 283 SARS-CoV-2 Case Information.

March 31, 2020

148. SARS-CoV-2-WA/CDC.

July 29, 2020

149. COVID-19 Vaccine Associated Parkinson's Disease, A Prion Disease Signal in the UK Yellow Card Adverse Event Database.

July 18, 2021

150. Pfizer UK Yellow Card Adverse Event Data.

June 30, 2021

151. Unexpected SARS-CoV-2 RNA Sequences.

May 30, 2020

152. Mask Analysis of SARS.

August 7, 2017

153. Fibonacci Analysis of SARS-CoV-2 Variants and Vaccine mRNA Spikes.

June 30, 2021

154. COVID-19 RNA Based Vaccines and Prion Disease.

January 18, 2021

155. Review of COVID Vaccines and Risk of Adverse Events Including Neurologic Disease.

April 10, 2021

156. Mullis PCR Patent.

July 28, 1987

157. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues.

May 6, 2021

158. Shedding is defined by FDA, HHS, and the Center for Biologics Evaluation and Research.

January 2020

159. SARS-CoV-2 Drug Vaccine Biologics are Gene Therapy According to FDA definition.
July 25, 2018
160. Daszak & Zhengli build a Gain-of-Function Coronavirus that inhibits protective human immune response. Paid for by NIAID.

May 11, 2016

161. Natural IgG and IgA Immunity Following Infection with SARS-CoV-2.

May 7, 2021

162. T-cell Receptor (TCR) Immunity to SARS-CoV-2 Following Infections with Influenza or Cytomegalovirus (CMV).

June 23, 2021

163. SARS-C0V-2 Isolation Sequence & Primers.

April 12, 2020

164. Original Chinese Patients with SARS-CoV-2.

January 24, 2020

165. Appendix for # 164.

January 24, 2020

166. SARS-CoV-2 Prion-like Domain (PLD) Increases Infectivity of this Virus.

March 29, 2020

167. Patients are NOT Receiving Adequate Informed Consent.

December 4, 2020

168. Evidence of Long Term Durable Natural Immunity to SARS-CoV-2 Following Infection.

July 20, 2021

169. SARS-CoV-2 Bayesian Analysis Concludes SARS-CoV-2 Was NOT Natural BUT Laboratory Developed.

January 29, 2021

170. House Foreign Affairs Committee Report Minority Staff. Origins-of-COVID-19 Report.

August 2021

Published Science


Gain of Function Research

With a paper trail from China's bat caves to North Carolina, to increase infectivity and virulence of virus.  Documents tracking the virus back to Wuhan with $3.5 million from U.S. National Institute of Health funding.​

min 2:15 - 2:30 


"There are viruses that exist in bat species, preprogrammed to jump between species and replicate just fine in humans.  We had no access to the viruses in China, all we had was access to the sequence."

- quoted main culprit: Dr. Ralph Baric - Professor of Microbiology and Immunology, University of North Carolina


'Bat-Woman" Dr. Shi Zhengli in the BSL-4 lab. She is the Director of the Centre for Emergence of Infectious Disease and Biosafety at the Wuhan Institute of Virology, a Biosafety Level Four Biocontainment Lab 


mRNA Transcription Capacity

Evidence shows that SARS-CoV-2 spike protein can Integrate into human DNA.

Image shows mRNA getting into brain cells (coloration added to enhance clarity)

  • Using the Reverse Transcriptase (RT) found in human platelets, CD4 (Helper Cells) and other cells carrying Long Interspersed Nuclear Elements (LINE-1); or by the HIV-RT. Research has shown that SARS-CoV-2 mRNA can insert itself into human DNA

  • LINE-1 averages 6,000 base pairs (bp) and comprises approximately 17% of human DNA

  • 80 -100 of these LINE-1 segments are known to retro transpose leading to insertions, deletions, and rearrangement of genetic material.



Presence of Prion-like Domain in Spike Protein

Prion-like domains are critical to SARS-CoV-2 virulence. Prions are associated with "Mad Cow Disease" and neuromuscular movement disorders seen in Parkinson's Disease and Alzheimer's.

Creutzfeldt–Jakob disease (CJD), also known as subacute spongiform encephalopathy or neurocognitive disorder due to prion disease, is a fatal degenerative brain disorder.[4][1] Early symptoms include memory problems, behavioral changes, poor coordination, and visual disturbances.[4] Later symptoms include dementia, involuntary movements, blindness, weakness, and coma.[4] About 70% of people die within a year of diagnosis.[4]



Masterclass on SARS-CoV-2

Mar 21, 2021

Richard Fleming

Also of note is the date of the interview with Daszak by the virologist. It originally aired December 9, 2019.


Almost a third of recovered Covid patients return to hospital in five months and one in eight die

Research has found a devastating long-term toll on survivors, with people developing heart problems, diabetes and chronic conditions


Paramedics transport a patient from the ambulance to the emergency department at the the Royal London Hospital
Researchers have called for urgent monitoring of people who have been discharged from hospital CREDIT: Barcroft Media 

Almost a third of recovered Covid patients will end up back in hospital within five months and one in eight will die, alarming new figures have shown.

Research by Leicester University and the Office for National Statistics (ONS) found there is a devastating long-term toll on survivors of severe coronavirus, with many people developing heart problems, diabetes and chronic liver and kidney conditions. 

Out of 47,780 people who were discharged from hospital in the first wave, 29.4 per cent were readmitted to hospital within 140 days, and 12.3 per cent of the total died.

The current cut-off point for recording Covid deaths is 28 days after a positive test, so it may mean thousands more people should be included in the coronavirus death statistics.

Researchers have called for urgent monitoring of people who have been discharged from hospital.

Study author Kamlesh Khunti, professor of primary care diabetes and vascular medicine at Leicester University, said: “This is the largest study of people discharged from hospital after being admitted with Covid.

“People seem to be going home, getting long-term effects, coming back in and dying. We see nearly 30 per cent have been readmitted, and that’s a lot of people. The numbers are so large.

“The message here is we really need to prepare for long Covid. It’s a mammoth task to follow up with these patients and the NHS is really pushed at the moment, but some sort of monitoring needs to be arranged.”

The study found that Covid survivors were nearly three and a half times more likely to be readmitted to hospital, and die, in the 140 days timeframe than other hospital outpatients. 

Prof Khunti said the team had been surprised to find that many people were going back in with a new diagnosis, and many had developed heart, kidney and liver problems, as well as diabetes.

He said it was important to make sure people were placed on protective therapies, such as statins and aspirin. 

“We don’t know if it’s because Covid destroyed the beta cells which make insulin and you get Type 1 diabetes, or whether it causes insulin resistance, and you develop Type 2, but we are seeing these surprising new diagnoses of diabetes,” he added.

“We’ve seen studies where survivors have had MRS scans and they’ve cardiac problems and liver problems.

“These people urgently require follow up and the need to be on things like aspirin and statins.” 

The new study was published on a pre-print server and is yet to be peer reviewed.  However  experts described the paper as “important”.

Commenting on the study on Twitter, Christina Pagel, director of the clinical operational research unit at University College London said: “This is such important work. Covid is about so much more than death. A significant burden of long-term illness after hospitalisation for Covid.”

Last year, researchers at North Bristol NHS Trust found that three quarters of virus patients treated at Bristol's Southmead Hospital were still experiencing problems three months later.

Symptoms included breathlessness, excessive fatigue and muscle aches, leaving people struggling to wash, dress and return to work.

Some patients say they have been left needing a wheelchair since contracting the virus, while others claim they can no longer walk up the stairs without experiencing chest pain.

In December, the ONS estimated that one in 10 people who catch coronavirus go on to suffer long Covid with symptoms lasting three months or more. 

Overall, roughly 186,000 people in private households in England in the week beginning November 22 were living with Covid-19 symptoms that had persisted for between five and 12 weeks, the most up-to-date ONS data shows.